the reality of
CONSIDER THESE DOZEN STATISTICS that shed
light on the unacceptable disparities:
Every pediatric-specific cancer is rare. The average age at diagnosis is 8.
In 2017, 15,780 children received cancer diagnoses.
Over 95% of pediatric cancer survivors will experience a significant side effect of cancer treatment by the age of 45.
As of 2017, only one targeted therapy was approved for a cancer which disproportionately affects children.
Prostate cancer, with a five-year cure rate nearing 100%, receives National Cancer Institute funding amounting to well over half the funding received for all childhood cancers combined.
Pediatric care centers face critical drugs shortages due to lack of sufficient economic incentive for developers and manufacturers.
Cancer is the leading cause of death among Asian Americans, Native Hawaiians, Pacific Islanders, and Hispanics.
African Americans have the highest mortality rate of any racial and ethnic group for all cancers combined.
Non-white patients are severely underrepresented in clinical studies. From 2015-2016, 76-79% of participants were Caucasian, 11-12% were Asian, and 5-7% were African American.
Over 60 cancers disproportionately affect veterans and the military. Almost two-thirds of those cancers are rare.
In 2018, only 25 cancers which disproportionately affect service members had an FDA-approved targeted therapy. The remainder are typically treated by surgery, radiation, and chemotherapy.